MX2020014031A - Proteinas heterodimericas y usos de las mismas. - Google Patents

Proteinas heterodimericas y usos de las mismas.

Info

Publication number
MX2020014031A
MX2020014031A MX2020014031A MX2020014031A MX2020014031A MX 2020014031 A MX2020014031 A MX 2020014031A MX 2020014031 A MX2020014031 A MX 2020014031A MX 2020014031 A MX2020014031 A MX 2020014031A MX 2020014031 A MX2020014031 A MX 2020014031A
Authority
MX
Mexico
Prior art keywords
heterodimeric proteins
proteins
immunotherapies
autoimmunity
cancer
Prior art date
Application number
MX2020014031A
Other languages
English (en)
Inventor
George Fromm
Taylor Schreiber
Silva Suresh De
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of MX2020014031A publication Critical patent/MX2020014031A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere, entre otros, a composiciones y métodos, incluyendo proteínas heterodiméricas que encuentran uso en el tratamiento de enfermedades, tales como inmunoterapias para el cáncer y autoinmunidad.
MX2020014031A 2018-06-21 2019-06-21 Proteinas heterodimericas y usos de las mismas. MX2020014031A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688167P 2018-06-21 2018-06-21
US201862703248P 2018-07-25 2018-07-25
PCT/US2019/038451 WO2019246508A1 (en) 2018-06-21 2019-06-21 Heterodimeric proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2020014031A true MX2020014031A (es) 2021-05-12

Family

ID=68983045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020014031A MX2020014031A (es) 2018-06-21 2019-06-21 Proteinas heterodimericas y usos de las mismas.

Country Status (10)

Country Link
US (3) US10995127B2 (es)
EP (1) EP3810172A4 (es)
JP (3) JP7439372B2 (es)
KR (1) KR20210025054A (es)
CN (1) CN112566650A (es)
AU (1) AU2019290192A1 (es)
BR (1) BR112020026112A2 (es)
CA (1) CA3103975A1 (es)
MX (1) MX2020014031A (es)
WO (1) WO2019246508A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210025054A (ko) * 2018-06-21 2021-03-08 샤턱 랩스 인코포레이티드 이형이량체 단백질 및 이의 용도
US20220306715A1 (en) * 2019-08-30 2022-09-29 Shattuck Labs, Inc. Chimeric proteins in autoimmunity
US20230226202A1 (en) * 2020-03-30 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Il-2/il15 compositions and methods of use thereof
KR20240007256A (ko) 2021-05-12 2024-01-16 어플라이드 바이오메디컬 사이언스 인스티튜트 이황화 결합된 결합 폴리펩타이드의 스크리닝 및 발현 방법
WO2022241057A1 (en) 2021-05-12 2022-11-17 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
WO2023205738A2 (en) * 2022-04-20 2023-10-26 Neptune Biosciences Llc Orthogonal il-21 receptor/cytokine systems
WO2023225488A1 (en) 2022-05-16 2023-11-23 Enkefalos Biosciences, Inc. Blood-brain barrier translocating peptides and related molecules and methods of use thereof
WO2024019984A1 (en) * 2022-07-18 2024-01-25 Cargo Therapeutics, Inc. Cytokine receptor switch polypeptides and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3872813B2 (ja) * 1994-05-18 2007-01-24 エス．ピー．アイ． シンセティック ペプチデス インコーポレイテッド ヘテロダイマーポリペプチド免疫原キャリア組成物および方法
IT1274350B (it) * 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
DE69733309T2 (de) * 1996-02-20 2006-01-19 Applied Research Systems Ars Holding N.V. Heterodimerebildende hybrid-proteine
DE69824039T2 (de) * 1997-12-08 2005-08-18 Lexigen Pharmaceuticals Corp., Lexington Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE316982T1 (de) * 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
ATE547525T1 (de) * 2000-08-08 2012-03-15 Zymogenetics Inc Lösliche zcyctor 11 cytokinrezeptoren
DE602005026407D1 (de) * 2004-07-09 2011-03-31 Variety Children S Hospital D B A Miami Children S Hospital Miami Materialien und verfahren zur stimulierung des immunsystems
EP2072527A1 (en) * 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
WO2011090762A1 (en) * 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
EP2550529B1 (en) * 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
US10017545B2 (en) * 2013-06-03 2018-07-10 University Of Maryland, College Park Compositions and vaccines comprising vesicles and methods of using the same
CN107124870A (zh) * 2014-09-17 2017-09-01 基因泰克公司 包含抗her2抗体和吡咯并苯并二氮杂*的免疫缀合物
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
US20180044404A1 (en) * 2015-03-05 2018-02-15 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
EP3325510A2 (en) * 2015-07-26 2018-05-30 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
BR112018006578A2 (pt) * 2015-10-01 2018-12-26 Heat Biologics, Inc. composições e métodos para juntar domínios extracelulares tipo i e tipo ii como proteínas quiméricas heterólogas
WO2017106061A1 (en) * 2015-12-14 2017-06-22 Macrogenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
US10906957B2 (en) * 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins
WO2018067991A1 (en) * 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US11332509B2 (en) * 2017-02-27 2022-05-17 Shattuck Labs, Inc. Methods of making and using extracellular domain-based chimeric proteins
KR20210025054A (ko) * 2018-06-21 2021-03-08 샤턱 랩스 인코포레이티드 이형이량체 단백질 및 이의 용도
US11098093B2 (en) * 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
US20220306715A1 (en) * 2019-08-30 2022-09-29 Shattuck Labs, Inc. Chimeric proteins in autoimmunity

Also Published As

Publication number Publication date
JP2023116718A (ja) 2023-08-22
US11780897B2 (en) 2023-10-10
CN112566650A (zh) 2021-03-26
JP2024057087A (ja) 2024-04-23
WO2019246508A1 (en) 2019-12-26
EP3810172A4 (en) 2022-04-20
US20210214409A1 (en) 2021-07-15
JP7439372B2 (ja) 2024-02-28
US10995127B2 (en) 2021-05-04
BR112020026112A2 (pt) 2021-04-06
CA3103975A1 (en) 2019-12-26
AU2019290192A1 (en) 2021-01-07
KR20210025054A (ko) 2021-03-08
US20200079831A1 (en) 2020-03-12
US20230220030A1 (en) 2023-07-13
EP3810172A1 (en) 2021-04-28
JP2021527700A (ja) 2021-10-14
JP7452932B2 (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
AU2021200367B2 (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
ZA201905488B (en) Tigit- and light-based chimeric proteins
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
MX2019012233A (es) Anticuerpos anti-sirpa.
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
WO2018069500A3 (en) ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
CL2018003582A1 (es) Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567)
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
PH12020550051A1 (en) Glp-1 compositions and uses thereof
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
PH12016501107B1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2021002294A (es) Terapias de combinacion que comprenden proteinas quimericas basadas en pd-1.
MX2021002286A (es) Terapias de combinacion.
MX2021008022A (es) Proteínas heterodiméricas para modular células t gamma delta.
MX2019009293A (es) Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos.
WO2020102243A3 (en) In-flow photooxygenation of aminothienopyridinones generates novel ptp4a3 phosphatase inhibitors
MX2017011903A (es) Composiciones para el tratamiento de enfermedades renales y/o hepaticas.